Serum sclerostin levels are positively related to bone mineral density in peritoneal dialysis patients: a cross-sectional study

Chronic kidney disease (CKD)–mineral and bone disorder (MBD) is a systemic disorder caused by alterations in mineral handling, bone and hormonal changes due to CKD, and subsequent cardiovascular disease and mortality; CKD–MBD becomes a potential target to improve CKD care outcomes referred by the KDIGO CKD–MBD guidelines [1]. CKD–MBD is characterized by a disruption in the homeostasis of the renal, skeletal, and cardiovascular systems. The injured kidney contributes to hyperphosphatemia, excessive bone resorption, and subsequent osteopenia in CKD patients with either high- or low-turnover bone disorders resulting in osteoporosis prevalence being higher in patients with CKD than in the general population [2‐4]. By accelerating ectopic mineralization, particularly vascular calcification, CKD–MBD extends beyond CKD-related bone disorders toward increasing cardiovascular risk and mortality by further aggravating vascular stiffness and promoting ventricular hypertrophy development. Over the past decade, numerous studies have reported that the wingless-type mouse mammary tumor virus integration site (Wnt)/β-catenin canonical signaling pathway is a major bone mass regulatory pathway [5]. Wnt signaling is mediated by the binding of Wnt ligands to a transmembrane receptor complex, composed of the frizzled receptor and either of the two coreceptors, the low-density lipoprotein receptor-related protein (LRP) 5 or LRP6 [6]. Wnt signaling activation reduces osteoblast and osteocyte apoptosis, induces osteoblastogenesis, and inhibits osteoclastogenesis [7]. These actions, resulting in subsequent increase in bone formation and bone density, may be crucial in CKD–MBD pathogenesis [8].

The Wnt signaling pathway is regulated by several inhibitors, whose regulatory action involves either preventing Wnt ligands from binding to receptors directly or binding to LRP5 or LRP6 (thus reducing the availability of these coreceptors to Wnt ligands). Of the main regulators in the Wnt pathway, dickkopf (DKK)-1 and particularly sclerostin have recently been studied comprehensively. DKK-1, a 28-kDa glycoprotein found in osteoblasts and osteocytes, inhibits the Wnt pathway by binding to LRP5, LRP6, and Kremen-1 (another coreceptor) to induce internalization of these coreceptors [9]. Similar to DKK-1, sclerostin is a 24-kDa glycoprotein, encoded by SOST, but secreted almost exclusively by osteocytes. Sclerostin inhibits the Wnt pathway by competing with Wnts for binding to LRP5 and LRP6 to antagonize the canonical Wnt signaling. In studies mainly on non-CKD population, sclerostin levels were correlated positively with age, male sex, diabetes, and bone mineral density (BMD) but inversely with physical activity and parathyroid hormone (PTH) levels [10‐14].

Patients with CKD have increased bone loss and low BMD risks followed by fractures because of the disturbance in mineral and bone metabolism [15, 16]. Recent CKD-MBD guidelines have updated that BMD assessment is sufficient for fracture prediction in patients with advanced CKD [17]. However, most studies correlating sclerostin with BMD and other CKD–MBD-related factors mainly involve nondialyzed CKD or hemodialysis (HD) patients and very few have been in the peritoneal dialysis (PD) population [18‐22]. Thus, this study explored serum sclerostin levels and their association with BMD and other CKD–MBD-related biomarkers in the PD patients.

Our findings demonstrated, for the first time in a PD population, that sclerostin levels are positively associated with BMD, an association that remained even after adjustment for various factors. Because gender and weight can have different effects on BMD, their contribution to the sclerostin–BMD association was also investigated. In the general population, particularly postmenopausal women, a positive correlation between BMD and sclerostin has been identified [11, 25‐27]. This relationship can also be observed in older men and patients with advanced CKD, including those receiving maintenance HD [11, 21, 28, 29]. However, this positive association between sclerostin and BMD cannot be well explained by the BMD-lowering effects of sclerostin, which was demonstrated by an interventional study, in which a lower risk of vertebral fractures was noted in postmenopausal women with osteoporosis after antagonizing sclerostin [30]. In addition, high physical activity, particularly weight-bearing activity, aided in reducing sclerostin levels and thus increased BMD [31]. In another study on healthy men, long-term bed rest reduced BMD and increased sclerostin levels [32]. These results disagree with the assumption that serum sclerostin levels increase and thus BMD decreases in older people and CKD or dialysis patients because their physical activity levels typically are low. Nevertheless, considering the causal inferences in this association from the opposite direction, a possible explanation could be higher BMD in men and patients with higher weights reflect higher total body skeletal mass with more osteocytes, the main sclerostin-producing cells [11].

Sclerostin levels also increase with age in nondialyzed CKD and HD patients [18, 33]. In 2015, Yamada et al. reported that serum sclerostin was positively associated with age in PD patients [34]. However, in the present study, patients with above-median sclerostin levels were characterized by older age, with only marginally statistical significance, probably because of our limited sample size.

Moreover, here, intact PTH levels were negatively associated with serum sclerostin levels (Spearman correlation coefficient adjusted for age and gender, r = − 0.357, P < 0.001). Intact PTH is a significant determinant of serum sclerostin levels in healthy premenopausal and postmenopausal women [10, 35], patients with primary hyperparathyroidism [14], HD patients [8], and PD patients [34], but not in patients with non-dialyzed CKD [18]. Although the PTH–sclerostin relationship was seen in our univariate and multivariate analyses, the effect size was marginal. Some of our patients had received parathyroidectomy, which may interfere with their intact PTH levels; thus, whether parathyroidectomy has a role in circulating sclerostin remains unclear. Because further subgroup analysis was limited by the sample size of our parathyroidectomy patients, we performed another analysis to test for the intact PTH–parathyroidectomy interaction for serum sclerostin levels; however, no significant interaction was noted (P for interaction = 0.440). Patients with a parathyroidectomy history are mostly present in the dialysis population; two studies have explored sclerostin levels in these dialysis patients [21, 34]. However, patients with parathyroidectomy were excluded by Cejka et al. (when including HD patients) and by Yamada et al. (when including PD patients). Hence, more data and studies to elucidate the relationship between serum intact PTH and sclerostin levels after parathyroidectomy in these dialysis patients are warranted.

Sclerostin is also positively associated with pulse wave velocity for arterial stiffness in postmenopausal women, nondialyzed CKD patients, HD patients, and kidney transplant recipients and thus could be a biomarker for the cardiovascular changes in the CKD–MBD spectrum [22, 25, 36, 37]. However, in our PD patients, such an association was absent between arterial stiffness and sclerostin. Although the results were nonsignificant in our PD patients, vascular stiffness could be a later presentation after sclerostin or BMD has changed. The evolving disturbances in the renal–skeletal–cardiovascular axis in the CKD–MBD may target osteoporosis with an early intervention to prevent further cardiovascular damage and improve long-term outcomes; thus, in the early CKD–MBD phase, sclerostin could both be a biomarker and an intervention target. However, we did not obtain this kind of association between arterial stiffness and sclerostin in the PD patients.

In addition, to explore the relationship between BMD and the bone-related biomarkers other than sclerostin, we compared the respective associations (Table 4). The relationship between DKK-1 and BMD disclosed inconsistent results in previous reports: DKK-1 had a negative correlation with BMD in diabetes and predialysis CKD patients [28, 38], but in postmenopausal women, HD patients, and people under steroid treatment, this relationship was not observed [21, 25, 39]; moreover, here, we did not find this correlation in our PD patients. Although both sclerostin and DKK-1 express Wnt antagonism, they are independent (not synergistic) regulators of Wnt signaling. DKK-1 and sclerostin do not bind simultaneously to LRP5; DKK-1 can displace sclerostin from a previously formed sclerostin-LRP5 complex [40]. In addition, compared with the BMD-sclerostin association, the lack of BMD-DKK-1 association may be related to DKK-1 not being highly expressed in adult bones unless it is activated by an insult. By contrast, sclerostin expression is downregulated when bone formation or normal skeletal maintenance is required, not merely when fractures occur [41]. The differences in study populations and the wider tissue distribution of DKK-1 compared with that of sclerostin may explain the varying results of their correlation with BMD [25]. FGF-23 is positively correlated significantly with BMD in older men and postmenopausal women [42‐44]. However, the association was not noted in the CKD or HD patients [45, 46]. After bone degradation, CTX, a bone resorption marker, is released into circulation and eventually excreted through urine [47]. CTX is negatively correlated with BMD in HD patients, but not PD patients [48, 49]—similar to our results. Because CTX is renally cleared, residual renal function may alter sclerostin levels. Here, we analyzed CTX results by stratifying our PD patients into anuric and nonanuric groups but observed no difference in CTX levels or total Kt/V between these two groups. According to a study on CTX in HD patients, CTX was nonsignificantly associated with the residual renal function, and CTX sampling time was suggested to be before dialysis because the concentration decreased after HD, implying some HD-related clearance [50]. Osteocalcin, produced by osteoblasts, is often considered a bone formation marker. Our results revealed that BMD is negatively correlated with osteocalcin after adjustments for age and gender; similar results were reported in predialysis CKD and HD patients [51, 52]. Nevertheless, here, the correlation between bone-related biomarkers other than sclerostin and BMD was not strong; however, the trends of the associations in this study were compatible with most of the previous reports. Further information enabling the elucidation of the bone-related biomarker relationships with BMD in PD patients is needed because the actual association may be merely masked by either our small sample size or our inclusion of younger patients with narrow age distribution.

Although our results demonstrated the sclerostin–BMD association, our clinical inference should be interpreted with caution because the selection of site for BMD measurement and quantification of sclerostin with different assays may demonstrate important differences. Lumbar BMD may increase if abdominal aortic calcification or spinal degeneration exists [53‐56]. Here, the review of pelvis and previous abdominal X-ray revealed that few of our enrolled patients had aorta calcification or severely degenerative spine, which could strongly influence spine BMD accuracy. Although BMD measurement is recommended by the KDIGO 2017 Clinical Practice Guideline Update [17], the choice of site for BMD measurement is not clearly stated and recommended. Four prospective studies of BMD and incident fractures in adults were reviewed in guideline development process. The purpose was for fracture prediction and the BMD results of hip or femoral neck were with a higher rate of prediction. However, a few dialysis patients receive total hip replacement surgery because the long-term use of steroid for glomerulonephritis in their predialysis phase has side effects and BMD at these sites cannot be measured. Therefore, in addition to fracture risk assessment, lumbar BMD may still have a role for the assessment of CKD-MBD syndrome, but the evaluation of factors affecting the accuracy of BMD measurement should be considered simultaneously. Regarding sclerostin measurement, Delanaye et al. reported that commercially available sclerostin ELISAs demonstrated marked differences in the values of measurement [57]. These differences potentially result from the manufacturer-provided antibodies being different, having crossreactivity with other proteins, and capturing both intact sclerostin and its degraded fragments. In the present study, ELISA for sclerostin may have detected both the intact molecule and its fragments; however, no information on the activity of degraded fragments of sclerostin is currently available. When exploring the relationship between sclerostin and its clinical or biochemical determinants, our results should be used with caution until a reference assay with high specificity for sclerostin is available.

This study has some limitations. First, similar to any cross-sectional observational study, our study confirmed the expected association, but a causal inference could not be made. To characterize the sclerostin–BMD relationship, a future longitudinal study may be needed. Second, our sample was relatively small and thus its statistical power may not have been sufficient for detecting potential confounding factors affecting sclerostin levels. Third, the biological variation in the serum levels of sclerostin and other bone-related biomarkers may cause some bias in a single measurement for each patient. Fourth, only lumbar spine BMD was measured and the correlation between sclerostin and BMD at other sites in PD patients was not investigated. In addition, we did not obtain information on the physical activities, which could be BMD determinants; however, dialysis patients are typically thought to have relatively low weight-bearing activities. Fifth, we did not collect peritoneal dialysate for sclerostin measurement and thus whether the clearance of sclerostin through peritoneal dialysate potentially interfered with our final result remains unclear. Nevertheless, the total Kt/V for urea in our patients, as a surrogate of sclerostin clearance through peritoneal dialysate, demonstrated no major effects for sclerostin in our analysis. Finally, sclerostin levels are considerably influenced by the assay used; our findings would not be immediately relevant if a different assay were adopted.

This is the first study demonstrating that serum sclerostin is significantly correlated with BMD in PD patients. The BMD of vertebrae was positively associated with sclerostin levels even after adjustment for multiple factors. The results add substantial evidence to the whole picture of CKD–MBD by connecting sclerostin to bone changes in the CKD–MBD spectrum. However, the detailed effects of sclerostin from the skeletal to vascular sides of the CKD–MBD spectrum remain unclear. Thus, future longitudinal studies elucidating the role of sclerostin in PD patients with CKD–MBD are warranted.